Cargando…
A single-center, randomized, parallel design study to evaluate the efficacy of donepezil in improving visuospatial abilities in patients with mild cognitive impairment using eye-tracker: the COG-EYE study protocol for a phase II trial
BACKGROUND: Cholinesterase inhibitors (ChEIs) decrease long-term cognitive decline in patients with Alzheimer’s disease (AD); however, there is little evidence that ChEIs affect cognitive test scores in patients with mild cognitive impairment (MCI). Conventional endpoints, such as cognitive tests or...
Autores principales: | Kim, Ko Woon, Wang, Qi, Koo, Se Hee, Shin, Byoung-Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513951/ https://www.ncbi.nlm.nih.gov/pubmed/36167553 http://dx.doi.org/10.1186/s13063-022-06781-0 |
Ejemplares similares
-
Donepezil for mild cognitive impairment in Parkinson’s disease
por: Baik, Kyoungwon, et al.
Publicado: (2021) -
Cognitive Impairment in Diabetes: Rationale and Design Protocol of the Cog-ID Study
por: Koekkoek, Paula S, et al.
Publicado: (2015) -
Does Consolidation of Visuospatial Sequence Knowledge Depend on Eye Movements?
por: Coomans, Daphné, et al.
Publicado: (2014) -
The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial
por: Rockwood, Kenneth, et al.
Publicado: (2007) -
The Tehran Eye Study: research design and eye examination protocol
por: Hashemi, Hassan, et al.
Publicado: (2003)